Fielmann (FIE) Q1 2026 earnings summary

Executive summary

• Achieved sales growth of 1.3% year-over-year to €613m in Q1 2026, outperforming the market despite adverse weather and macroeconomic headwinds.

• Maintained strong profitability and market share gains across Europe, with notable resilience in Germany, Austria, Switzerland, and Spain.

• US business continued to progress, with investments in platform transformation and expanded doctor capacity supporting future growth.

Financial highlights

• Total consolidated sales reached €613m, up 1.3% year-over-year; at constant currency, sales grew 2.3%.

• Adjusted EBITDA rose to €149m (+1.0%), with a margin of 24.3%.

• Adjusted EBT increased to €81m (+1.8%), with a margin of 13.2%.

• Net profit attributable to shareholders was €55.7m, up 2.1% year-over-year.

• Earnings per share (undiluted/diluted) were €0.66.

Outlook and guidance

• Forecasts consolidated sales growth of 5–7% for FY2026, targeting €2.55bn–€2.60bn.

• Expects Adjusted EBITDA margin around 23% and Adjusted EBT margin between 12% and 13% for 2026.

• Anticipates continued macroeconomic and geopolitical headwinds, with investments expected to temporarily weigh on profitability.